Form 4: Atossa Therapeutics Director Acquires Stock Options

Stephen J. Galli, a director of Atossa Therapeutics, acquired stock options exercisable for 125,000 shares of common stock.

Summary

• Stephen J. Galli, a director of Atossa Therapeutics, filed a Form 4.
• On May 15, 2025, Galli acquired options to purchase 125,000 shares of Atossa Therapeutics common stock at an exercise price of $0.99 per share.
• The options vest quarterly over 12 months following the grant date, contingent upon Galli's continued service.
• The options expire on May 15, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a standard transaction of stock options to a director, which is neither overtly positive nor negative.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.

Stakeholder Impact

• The acquisition of stock options by a director could potentially increase shareholder value if the director's actions lead to improved company performance.

Key Dates

Keywords

Atossa Therapeutics, Stock Options, Form 4, Director, Beneficial Ownership, Galli, ATOS